S007 Advanced Therapeutics for Complex Dermatologic Disease
DESCRIPTION
The skin is a window into the inner workings of the immune system and the rest of the body. As dermatologists, we play a critical role in diagnosis and management, but often will partner with other specialties to treat complex disease. In this session, we hope to demystify the systemic therapeutics that are often used in treatment of complex skin disease, and in areas where appropriate, will demonstrate how dermatologists can reclaim the management of systemic disease.
LEARNING OBJECTIVES
Develop treatment algorithms for complex medical dermatologic conditions, namely: connective tissue disease, blistering disorders, neutrophilic dermatoses, cutaneous lymphomas, hidradenitis, GVHD, and cutaneous irAEs.
Manage complications that may arise as a result of systemic therapeutic options prescribed by the dermatologist.
Discuss where dermatologic management can extend in areas of medicine that have traditionally been controlled by other specialties.
SCHEDULE
9:00 AM
Update on Therapies for Cutaneous Chronic Graft-Versus-Host Disease
Michael Stephens, MD, FAAD
9:25 AM
Integrating Newer Therapies in the Treatment of Advanced CTCL
Youn H. Kim, MD, FAAD
9:50 AM
Advanced Treatment Approaches for Hidradenitis Suppurativa
Madeline DeWane, MD
10:15 AM
Neutrophilic Dermatoses: Updates and Advanced Therapeutic Approaches
Misha Rosenbach, MD, FAAD
10:40 AM
Rethinking Treatment: Approaches to Complex Bullous Diseases
Helena Pasieka, MD, FAAD
11:05 AM
Rheum for improvement: What's new in Rheumatologic Dermatology
Scott Elman, MD, FAAD
11:30 AM
Checking in on Checkpoint Toxicities: Treatment Considerations for Cutaneous Immune Related Adverse Events
Steven T. Chen, MD, MPH, FAAD
DIRECTOR
Steven T. Chen, MD, MPH, FAAD
SPEAKERS
Madeline DeWane, MD
Scott Elman, MD, FAAD
Youn H. Kim, MD, FAAD
Helena Pasieka, MD, FAAD
Misha Rosenbach, MD, FAAD
Michael Stephens, MD, FAAD
DISCLOSURES
Steven T. Chen, MD, MPH, FAAD
AbbVie – Advisory Board(Honoraria); Vertex Pharmaceuticals Incorporated – Employee (w-2 relationship)(Salary); VisualDx – Independent Contractor(Fees);
Madeline DeWane, MD
VeraDermics Inc. – Founder(No Compensation Received);
Scott Elman, MD, FAAD
Biogen – Consultant(Fees); Blueprint Medicines – Advisory Board(Fees); EMD Serono – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding);
Youn H. Kim, MD, FAAD
CRISPR Therapeutics – Investigator(Grants/Research Funding); Dren Bio, Inc – Investigator(Grants/Research Funding), Other(No Compensation Received); Innate Pharma S.A. – Other(No Compensation Received); Innate Pharma, S.A. – Investigator(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); LIBO Pharma Corp. – Advisory Board(Honoraria); ONO-Pharma – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Secura Bio – Advisory Board(Honoraria); Takeda Pharmaceuticals USA Inc – Speaker(Honoraria); Treeline – Investigator(Grants/Research Funding);
Helena Pasieka, MD, FAAD
No financial relationships exist with ineligible companies.
Misha Rosenbach, MD, FAAD
Google Ventures – Consultant (1099 relationship)(Honoraria); J&J Innovative Medicine – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); OpenEvidence – Advisory Board(Other Financial Benefit); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding);
Michael Stephens, MD, FAAD
No financial relationships exist with ineligible companies.